All articles by Vishnu Priyan
Vishnu Priyan
Armata concludes Phase Ib/IIa Pseudomonas aeruginosa infection therapy trial
The company anticipates topline findings from the trial in the first quarter of next year.
Health Canada grants clearance for Ceapro’s anti-inflammatory therapy trial
Participant recruitment in the trial is expected to begin early next year.
US FDA grants approval for Gradalis’ Phase III ovarian cancer trial
Progression-free survival is the primary endpoint while overall survival is a crucial secondary endpoint of the trial.
Italy grants clearance for Moleculin’s Phase I/II leukaemia therapy trial
The treatment of the first subject in Italy is expected in the first quarter of next year.
Beckley Psytech begins Phase IIa treatment resistant depression trial
Anticipated to enrol the first subject in January next year, the trial will evaluate the impact of one dose of BPL-003.
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
Kira gets clearance for bifunctional biologic trial in China, Australia
The trials will assess the safety, efficacy, tolerability, PK and PD of KP104 in IgAN and C3G patients.
Imago doses first subject in Phase II myelofibrosis treatment trial
The trial will evaluate the safety and efficacy of bomedemstat plus ruxolitinib for 28 days.
Biocon commences Phase II trial of ulcerative colitis therapy
The trial will enrol up to 90 subjects at multiple trial sites in India.
Synaptogenix reports data from Phase II Alzheimer’s trial
According to the findings, the trial failed to meet the primary endpoint with statistical significance.
Frequency doses first patient in Phase Ib sensorineural hearing loss trial
The company plans to report clinical data from the trial in the second half of next year.